References
- Janikova A, Bortlicek Z, Campr V, et al. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change standard therapy? Leuk Lymphoma 2015; 56:2350–2356.
- Feinstein AR, Sosin DM, and Wells CK.The Will Rogers Phenomenon – Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985; 312:1604–1608.
- Basu S and Alavi A.Staging with PET and the “Will Rogers”effect: redefining prognosis and survival in patients with cancer. Eur J Nucl Med Mol Imaging 2008; 35:1–4.
- Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 2014; 32:3059–3067.
- Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: Consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol 2014; 32:3048–3058.
- Wirth A, Foo M, Seymour JF, MacManus MP, Hicks RJ. Impact of [18F]fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-Hodgkin lymphoma. Int J Rad Oncol Biol Phys 2008; 71:213–219
- Berinstein NL, Reis MD, Ngan BY, et al.Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early-stage and advanced-stage follicular lymphoma. J Clin Oncol 1993; 11:1344–1352.
- Cheson BD, Horning SJ, Coiffier B, et al.Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17:1244–1253.
- Herfarth K, Englehard M, Borchmann P, et al. Treatment of early stage nodal follicular lymphoma using involved field radiotherapy and rituximab: Preliminary results of the Mir trial. Blood 2012; 120: abst 1634.
- Haidenberger A, Gunsilius E, Embacher S, Lukas P. Kombinierte Radio/Immuntherapie mit MabThera (Rituximab) bei Patienten mit CD20 + follikularen Non-Hodgkin-Lymphomen im Stadium I, II, und limitiertem Stadium III – Prasentation der OGRO Studie. Strahlentherapie und Onkologie 2008; 184:186.
- clinicaltrials.gov NCT No:NCT01473628
- Australian and New Zealand Clinical Trials Registry: ACTRN12607000112460